Therapeutic applications of aptamers

Bibliography

• Zamecnik PC, Stephenson ML. Inhibition of Rous sarcoma virus replication and cell transformation by a specific oligodeoxynucleotide. Proc Natl Acad Sci USA 1978;75:280-4
   PubMed Web of Science ®Google Scholar
• Bennett CF, Cowsert LM. Antisense oligonucleotides as a tool for gene functionalization and target validation. Biochim Biophys Acta 1999;1489:19-30
   PubMed Web of Science ®Google Scholar
• Zamore PD. RNA interference: listening to the sound of silence. Nat Struct Biol 2001;8:746-50
   PubMedGoogle Scholar
• Martineau HM, Pyrah IT. Review of the application of RNA interference technology in the pharmaceutical industry. Toxicol Pathol 2007;35:327-36
   PubMed Web of Science ®Google Scholar
• Pérez-Ruiz M, Barroso-delJesus A, Berzal-Herranz A. Specificity of the hairpin ribozyme. J Biol Chem 1999;274:29376-80
   PubMed Web of Science ®Google Scholar
• Peracchi A. Prospects for antiviral ribozymes and deoxyribozymes. Rev Med Virol 2004;14:47-64
   PubMed Web of Science ®Google Scholar
• Ban E, Dupré L, Hermann E, et al. CpG motifs induce Langerhans cell migration in vivo. Int Immunol 2000;12:737-45
   PubMed Web of Science ®Google Scholar
• Friedberg JW, Kim H, McCauley M, et al. Combination immunotherapy with a CpG oligonucleotide (1018 ISS) and rituximab in patients with non-Hodgkin lymphoma: increased interferon-alpha/beta-inducible gene expression, without significant toxicity. Blood 2005;105:489-95
   PubMed Web of Science ®Google Scholar
• White RR, Sullenger BA, Rusconi CP. Developing aptamers into therapeutics. J Clin Invest 2000;106:929-34
   PubMed Web of Science ®Google Scholar
• Rimmele M. Nucleic acid aptamers as tools and drugs: recent developments. Chembiochem 2003;4:963-71
   PubMed Web of Science ®Google Scholar
• Matveeva O, Felden B, Audlin S, et al. A rapid in vitro method for obtaining RNA accessibility patterns for complementary DNA probes: correlation with an intracellular pattern and known RNA structures. Nucleic Acid Res 1997;25:5010-16
   PubMed Web of Science ®Google Scholar
• Prakash TP, Bhat B. 2′-Modified oligonucleotides for antisense therapeutics. Curr Top Med Chem 2007;7:641-9
   PubMed Web of Science ®Google Scholar
• Sierakowska H, Sambade M, Agrawal S, Kole R. Repair of thalassemic human β-globin mRNA in mammalian cells by antisense oligonucleotides. Proc Natl Acad Sci USA 1996;93:12840-4
   PubMed Web of Science ®Google Scholar
• Jabs DA, Griffiths PD. Fomivirsen for the treatment of cytomegalovirus retinitis. Am J Ophthalmol 2002;133:552-6
   PubMed Web of Science ®Google Scholar
• Tarhini AA, Kirkwood JM. Oblimersen in the treatment of metastatic melanoma. Future Oncol 2007;3:263-71
   PubMedGoogle Scholar
• Fire A, Xu SQ, Montgomery MK, et al. Potent and specific genetic interference by double-stranded RNA in Caenorhabtidis elegans. Nature 1998;391:806-11
   PubMed Web of Science ®Google Scholar
• Elbashir SM, Harborth J, Lendeckel W, et al. Duplexes of 21-nucleotide RNA mediate RNA interference in cultured mammalian cells. Nature 2001;411:494-8
   PubMed Web of Science ®Google Scholar
• de Fougerolles A, Vornlocher HP, Maraganore J, Lieberman J. Interfering with disease: a progress report on siRNA-based therapeutics. Nat Rev Drug Discov 2007;6:443-53
   PubMed Web of Science ®Google Scholar
• Shen J, Samul R, Silva RL, et al. Suppression of ocular neovascularization with siRNA targeting VEGF receptor. Gene Ther 2006;13:25-34
   Google Scholar
• Gurrier-Takada C, Gardiner K, Marsh T, et al. The RNA moiety of ribonuclease P is the catalytic subunit of the enzyme. Cell 1983;35:849-57
   PubMed Web of Science ®Google Scholar
• Cech TR, Zaug AJ, Grabowski PJ. In vitro splicing of the ribosomal RNA precursor of Tetrahymena: involvement of a guanosine nucleotide in the excision of the intervening sequence. Cell 1981;27:487-96
   PubMed Web of Science ®Google Scholar
• Zhou C, Bahner IC, Larson GP, et al. Inhibition of HIV-1 in human T-lymphocytes by retrovirally transduced anti-Tat and Rev hammerhead ribozymes. Gene 1994;149:33-9
   PubMed Web of Science ®Google Scholar
• Weerasinghe M, Liem SE, Asad S, et al. Resistance to human immunodeficiency virus type-1 (HIV-1) infection in human CD4+ lymphocyte-derived cell lines conferred by using retroviral vectors expressing an HIV-1 RNA-specific ribozyme. J Virol 1991;65:5531-4
   PubMed Web of Science ®Google Scholar
• Lo KM, Biasolo MA, Dehni G, et al. Inhibition of replication of HIV-1 by retroviral vectors expressing Tat antisense and anti-Tat ribozyme RNA. Virology 1992;190:176-83
   PubMed Web of Science ®Google Scholar
• Lieber A, He CY, Polyak SJ, et al. Elimination of hepatitis C virus RNA in infected human hepatocytes by adenovirus-mediated expression of ribozymes. J Virol 1996;70:8782-91
   PubMed Web of Science ®Google Scholar
• Usman N, Blatt LM. Nuclease-resistant synthetic ribozymes: developing a new class of therapeutics. J Clin Invest 2000;106:1197-202
   PubMed Web of Science ®Google Scholar
• Manns MP, McHutchison JG, Gordon SC, et al. PEG-interferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001;358:958-65
   PubMed Web of Science ®Google Scholar
• Pockros PJ. Developments in the treatment of chronic hepatitis C. Expert Opin Investig Drugs 2002;11:515-23
   PubMed Web of Science ®Google Scholar
• Yamamoto S, Yamamoto T, Nojima Y, et al. Discovery of immunostimulatory CpG-DNA and its application to tuberculosis vaccine development. Jpn J Infect Dis 2002;55:37-44
   PubMed Web of Science ®Google Scholar
• Mullen GE, Aebig JA, Dobrescu G, et al. Enhanced antibody production in mice to the malaria antigen AMA1 by CPG 7909 requires physical association of CpG and antigen. Vaccine 2007;25:5343-7
   PubMed Web of Science ®Google Scholar
• Kurreck J. Antisense technologies. Improvements through novel chemical modifications. Eur J Biochem 2003;270:1628-44
   PubMedGoogle Scholar
• Shi H, Fan X, Sevilimedu A, Lis JT. RNA aptamers directed to discrete functional sites on a single protein structural domain. Proc Natl Acad Sci USA 2007;104:3742-6
   PubMed Web of Science ®Google Scholar
• Zhao X, Shi H, Sevilimedu A, et al. An RNA aptamer that interferes with the DNA binding of the HSF transcription activator. Nucleic Acids Res 2006;34:3755-61
   PubMed Web of Science ®Google Scholar
• Hallegger M, Taschner A, Jantsch MF. RNA aptamers binding the double-stranded RNA-binding domain. RNA 2006;12:1993-2004
   PubMed Web of Science ®Google Scholar
• Sassone-Corsi P. Coupling gene expression to cAMP signalling: role of CREB and CREM. Int J Biochem Cell Biol 1998;30:27-38
   PubMed Web of Science ®Google Scholar
• Heyduck E, Heyduck T. Nucleic acid-based fluorescence sensors for detecting proteins. Anal Chem 2005;77:1147-56
   PubMed Web of Science ®Google Scholar
• Hamaguchi N, Ellington A, Stanton M. Aptamer beacons for the direct detection of proteins. Anal Biochem 2001;294:126-31
   PubMed Web of Science ®Google Scholar
• Drabovich AP, Okhonin V, Berezovski M, Krylov SN. Smart aptamers facilitate multi-probe affinity analysis of proteins with ultra-wide dynamic range of measured concentrations. J Am Chem Soc 2007;129:7260-1
   PubMed Web of Science ®Google Scholar
• Fredriksson S, Gullberg M, Jarvius J, et al. Protein detection using proximity-dependent DNA ligation assays. Nat Biotechnol 2002;20:473-7
   PubMed Web of Science ®Google Scholar
• Niu W, Jiang N, Hu Y. Detection of proteins based on amino acid sequences by multiple aptamers against tripeptides. Anal Biochem 2007;362:126-35
   PubMed Web of Science ®Google Scholar
• Carlson B. Aptamers: the new frontier in drug development?. Biotechnol Healthcare 2007;31-6
   Google Scholar
• Petach H, Ostroff R, Greef C, Husar GM. Processing of photoaptamer microarrays. Methods Mol Biol 2004;264:101-10
   PubMedGoogle Scholar
• Nishihira A, Ozaki H, Wakabayashi M, et al. Detection of biomolecule by aptamer beacon. Nucleic Acids Symp Ser (Oxf) 2004;48:135-6
   PubMedGoogle Scholar
• Yamamoto R, Baba T, Kumar PK. Molecular beacon aptamer fluoresces in the presence of Tat protein of HIV-1. Genes Cells 2000;5:389-96
   PubMed Web of Science ®Google Scholar
• Romig TS, Bell C, Drolet DW. Aptamer affinity chromatography: combinatorial chemistry applied to protein purification. J Chromatogr B Biomed Sci Appl 1999;731:275-84
   PubMed Web of Science ®Google Scholar
• Hermann T, Patel DJ. Adaptive recognition by nucleic acid aptamers. Science 2000;287:820-5
   PubMed Web of Science ®Google Scholar
• Tuerk C, Gold L. Systematic evolution of ligands by exponential enrichment: RNA ligands to bacteriophage T4 DNA polymerase. Science 1990;249:505-10
   PubMed Web of Science ®Google Scholar
• Ellington AD, Szostak JW. In vitro selection of RNA molecules that bind specific ligands. Nature 1990;346:818-22
   PubMed Web of Science ®Google Scholar
• Eaton B. The joys of in vitro selection: chemically dressing oligonucleotides to satiate protein targets. Curr Opin Chem Biol 2005;1:10-16
   Google Scholar
• Osbourn J, Jermutus L, Duncan A. Current methods for the generation of human antibodies for the treatment of autoimmune diseases. Drug Discov Today 2003;8:845-51
   PubMed Web of Science ®Google Scholar
• Gold L. mRNA display: diversity matters during in vitro selection. Proc Natl Acad Sci USA 2001;98:4825-6
   PubMed Web of Science ®Google Scholar
• Qin W, Zhao A, Han Y, et al. A novel technique for efficient construction of large scFv libraries. Mol Biotechnol 2007;37:201-5
   PubMed Web of Science ®Google Scholar
• Lipovsek D, Plückthun A. In-vitro protein evolution by ribosome display and mRNA display. J Immunol Methods 2004;290:51-67
   PubMed Web of Science ®Google Scholar
• Nieuwlandt D, Wecker M, Gold L. In vitro selection of RNA ligands to substance P. Biochemistry 1995;34:5651-9
   PubMed Web of Science ®Google Scholar
• Theis MG, Knorre A, Kellersch B, et al. Discriminatory aptamer reveals serum response element transcription regulated by cytohesin-2. Proc Natl Acad Sci USA 2004;101:11221-6.
   PubMed Web of Science ®Google Scholar
• Ng EWM, Shima DT, Calias P, et al. Pegaptanib, a targeted anti-VEGF aptamer for ocular vascular disease. Nat Rev Drug Discov 2006;5:123-32
   PubMed Web of Science ®Google Scholar
• Martino L, Virno A, Randazzo A, et al. A new modified thrombin binding aptamer containing a 5′-5′ inversion of polarity site. Nucleic Acid Res 2006;34:6653-62
   PubMed Web of Science ®Google Scholar
• Rusconi CP, Scardino E, Layzer J, et al. RNA aptamers as reversible antagonists of coagulation factor IXa. Nature 2002;419:90-4
   PubMed Web of Science ®Google Scholar
• Corrias MV, Guarnaccia F, Ponzoni M. Bioavailability of antisense oligonucleotides in neuroblastoma cells: comparison of efficacy among different types of molecules. J Neurooncol 1997;31:171-80
   PubMed Web of Science ®Google Scholar
• Wolfrum C, Shi S, Jayaprakash KN, et al. Mechanisms and optimization of in vivo delivery of lipophilic siRNAs. Nat Biotechnol 2007;25:1149-57
   PubMed Web of Science ®Google Scholar
• Milani S, Bombelli FB, Berti D, Baglioni P. Nucleolipoplexes: a new paradigm for phospholipids bilayer-nucleic acid interactions. J Am Chem Soc 2007;129:11664-5
   PubMed Web of Science ®Google Scholar
• Shi H, Hoffman BE, Lis JT. RNA aptamers as effective protein antagonists in a multicellular organism. Proc Natl Acad Sci USA 1999;96:10033-8
   PubMed Web of Science ®Google Scholar
• Heldin CH, Rubin K, Pietras K, Ostman A. High interstitial fluid pressure – an obstacle in cancer therapy. Nat Rev Cancer 2004;4:806-13
   PubMed Web of Science ®Google Scholar
• Floege J, Ostendorf T, Janssen U, et al. Novel approach to specific growth factor inhibition in vivo: antagonism of platelet-derived growth factor in glomerulonephritis by aptamers. Am J Pathol 1999;154:169-79
   PubMed Web of Science ®Google Scholar
• Collett JR, Cho EJ, Lee JF, et al. Functional RNA microarrays for high-throughput screening of antiprotein aptamers. Anal Biochem 2005;338:113-23
   PubMed Web of Science ®Google Scholar
• Mairal T, Özalp VC, Sánchez PL, et al. Aptamers: molecular tools for analytical applications. Anal Bioanal Chem 2007; published online 21 June 2007, doi: 10.1007/s00216-007-1346-4
   PubMedGoogle Scholar
• Farokhzad OC, Jon S, Khademhosseini A, et al. Nanoparticle–aptamer bioconjugates: a new approach for targeting prostate cancer cells. Cancer Res 2004;64:7668-72
   PubMed Web of Science ®Google Scholar
• Farokhzad OC, Cheng J, Teply BA, et al. Targeted nanoparticle–aptamer bioconjugates for cancer chemotherapy in vivo. Proc Natl Acad Sci USA 2006;103:6315-20.
   PubMed Web of Science ®Google Scholar
• Chu TC, Marks JW, Lavery LA, et al. Aptamer:toxin conjugates that specifically target prostate tumor cells. Cancer Res 2006;66:5989-92
   PubMed Web of Science ®Google Scholar
• Jellinek D, Green LS, Bell C, Janjic N. Inhibition of receptor binding by high-affinity RNA ligands to vascular endothelial growth factor. Biochemistry 1994;33:10450-6
   PubMed Web of Science ®Google Scholar
• Ruckman J, Green LS, Beeson J, et al. 2′-Fluoropyrimidine RNA-based aptamers to the 165-amino acid form of vascular endothelial growth factor (VEGF165). Inhibition of receptor binding and VEGF-induced vascular permeability through interactions requiring the exon 7-encoded domain. J Biol Chem 1998;273:20556-67
   PubMed Web of Science ®Google Scholar
• Bell C, Lynam E, Landfair DJ, et al. Oligonucleotide NX1838 inhibits VEGF165-mediated cellular responses in vitro. In Vitro Cell Dev Biol Anim 1999;35:533-42
   PubMed Web of Science ®Google Scholar
• Tucker CE, Chen LS, Judkins MB, et al. Detection and plasma pharmacokinetics of an anti-vascular endothelial growth factor oligonucleotide-aptamer (NX1838) in rhesus monkeys. J Chromatogr B Biomed Sci Appl 1999;732:203-12
   PubMed Web of Science ®Google Scholar
• Gragoudas ES, Adamis AP, Cunningham ET, et al. VEGF inhibition study in ocular neovascularization clinical trial group. Pegaptanib for neovascular age-related macular degeneration. N Engl J Med 2004;351:2805-16
   Google Scholar
• D'Amico DJ, Masonson HN, Patel M, et al.; VEGF inhibition study in ocular neovascularization (VISION) clinical trial group. Pegaptanib sodium for neovascular age-related macular degeneration: two-year safety results of the two prospective, multicenter, controlled clinical trials. Ophthalmology 2006;113:992-1001
   PubMed Web of Science ®Google Scholar
• Pendergrast PS, Marsh HN, Grate D, et al. Nucleic acid aptamers for target validation and therapeutic applications. J Biomol Techniq 2005;16:224-34
   PubMedGoogle Scholar
• Rusconi CP, Roberts JD, Pitoc GA, et al. Antidote-mediated control of an anticoagulant aptamer in vivo. Nat Biotechnol 2004;22:1423-8
   PubMed Web of Science ®Google Scholar
• Bates PJ, Kahlon JB, Thomas SD, et al. Antiproliferative activity of G-rich oligonucleotides correlates with protein binding. J Biol Chem 1999;274:26369-77
   PubMed Web of Science ®Google Scholar
• Girvan AC, Teng Y, Casson LK, et al. AGRO100 inhibits activation of nuclear factor-κB (NF-κB) by forming a complex with NF-κB essential modulator (NEMO) and nucleolin. Mol Cancer Ther 2006;5:1790-9
   PubMed Web of Science ®Google Scholar
• Xu X, Hamhouyia F, Thomas SD, et al. Inhibition of DNA replication and induction of S phase cell cycle arrest by G-rich oligonucleotides. J Biol Chem 2001;276:43221-30
   PubMed Web of Science ®Google Scholar
• Dapić V, Abdomerović V, Marrington R, et al. Biophysical and biological properties of quadruplex oligodeoxyribonucleotides. Nucleic Acids Res 2003;31:2097-107
   PubMed Web of Science ®Google Scholar
• Dapić V, Bates PJ, Trent JO, et al. Antiproliferative activity of G-quartet-forming oligonucleotides with backbone and sugar modifications. Biochemistry 2002;41:3676-85
   PubMed Web of Science ®Google Scholar
• Laber DA, Choudry MA, Taft BS, et al. A Phase I study of AGRO100 in advanced cancer. J Clin Oncol 2004;22:3112
   Google Scholar
• James W. Aptamers in the virologists' toolkit. J Gen Virol 2007;88:351-64
   PubMed Web of Science ®Google Scholar
• Tuerk C, MacDougal S, Gold L. RNA pseudoknots that inhibit human immunodeficiency virus type 1 reverse transcriptase. Proc Natl Acad Sci USA 1992;89:6988-92
   PubMed Web of Science ®Google Scholar
• Levine BL, Humeau LM, Boyer J, et al. Gene transfer in humans using a conditionally replicating lentiviral vector. Proc Natl Acad Sci USA 2006;103:17372-7
   PubMed Web of Science ®Google Scholar
• Günzburg W, Mhashilkar AM, Hindi M. Technology evaluation: StealthVector (HIV) Enzo. Curr Opin Mol Ther 1999;1:651-7
   PubMed Web of Science ®Google Scholar
• Joshi PJ, North TW, Prasad VR. Aptamers directed to HIV-1 reverse transcriptase display greater efficacy over small hairpin RNAs targeted to viral RNA in blocking HIV-1 replication. Mol Ther 2005;11:677-86
   PubMed Web of Science ®Google Scholar
• Fisher TS, Joshi P, Prasad VR. Mutations that confer resistance to template-analog inhibitors of human immunodeficiency virus (HIV) type 1 reverse transcriptase lead to severe defects in HIV replication. J Virol 2002;76:4068-72
   PubMed Web of Science ®Google Scholar
• Held DM, Kissel JD, Saran D, et al. Differential susceptibility of HIV-1 reverse transcriptase to inhibition by RNA aptamers in enzymatic reactions monitoring specific steps during genome replication. J Biol Chem 2006;281:25712-22
   PubMed Web of Science ®Google Scholar
• Held DM, Kissel JD, Thacker SJ, et al. Cross-clade inhibition of recombinant human immunodeficiency virus type 1 (HIV-1), HIV-2, and simian immunodeficiency virus SIVcpz reverse transcriptases by RNA pseudoknot aptamers. J Virol 2007;81:5375-84
   PubMed Web of Science ®Google Scholar
• Khati M, Schuman M, Ibrahim J, et al. Neutralization of infectivity of diverse R5 clinical isolates of human immunodeficiency virus type 1 by gp120-binding 2′F-RNA aptamers. J Virol 2003;77:12692-8
   PubMed Web of Science ®Google Scholar
• Dey AK, Khati M, Tang M, et al. An aptamer that neutralizes R5 strains of human immunodeficiency virus type 1 blocks gl120-CCR5 interaction. J Virol 2005;79:13806-10
   PubMed Web of Science ®Google Scholar
• Fisher TS, Joshi P, Prasad VR. HIV-1 reverse transcriptase mutations that confer decreased in vitro susceptibility to anti-RT DNA aptamer RT1t49 confer cross resistance to other anti-RT aptamers but not to standard RT inhibitors. AIDS Res Ther 2005;2:8-17
   PubMedGoogle Scholar
• Kissel JD, Held DM, Hardy RW, Burke DH. Active site binding and sequence requirements for inhibition of HIV-1 reverse transcriptase by the RT1 family of single-stranded DNA aptamers. Nucleic Acids Res 2007;35:5039-50
   PubMed Web of Science ®Google Scholar
• Andreola ML, Pileur F, Calmels C, et al. DNA aptamers selected against the HIV-1 RNase H display in vitro antiviral activity. Biochemistry 2001;40:10087-94
   PubMed Web of Science ®Google Scholar
• Jayasena SD. Aptamers: an emerging class of molecules that rival antibodies in diagnostics. Clin Chem 1999;45:1628-50
   PubMed Web of Science ®Google Scholar
• Presta LG. Engineering of therapeutic antibodies to minimize immunogenicity and optimize function. Adv Drug Deliv Rev 2006;58:640-56
   PubMed Web of Science ®Google Scholar
• Lu M, Adamis AP. Molecular biology of choroidal neovascularization. Ophthalmol Clin North Am 2006;19:323-34
   PubMedGoogle Scholar
• Bai J, Banda N, Lee NS, et al. RNA-based anti-HIV-1 gene therapeutic constructs in SCID-hu mouse model. Mol Ther 2002;6:770-82
   PubMed Web of Science ®Google Scholar
• Bergers G, Song S, Meyer-Morse N, et al. Benefits of targeting both pericytes and endothelial cells in the tumor vasculature with kinase inhibitors. J Clin Invest 2003;111:1287-95
   PubMed Web of Science ®Google Scholar
• Faulhammer D, Eschgfäller B, Stark S, et al. Biostable aptamers with antagonistic properties to the neuropeptide nociceptin/orphanin FQ. RNA 2004;10:516-27
   PubMed Web of Science ®Google Scholar
• Hicke BJ, Watson SR, Koenig A, et al. DNA aptamers block L-selectin function in vivo. Inhibition of human lymphocyte trafficking in SCID mice. J Clin Invest 1996;98:2688-92
   PubMed Web of Science ®Google Scholar
• Wiegand TW, Williams PB, Dreskin SC, et al. High-affinity oligonucleotide ligands to human IgE inhibit binding to FCE receptor. J Immunol 1996;157:221-30
   PubMed Web of Science ®Google Scholar
• Hwang B, Han K, Lee SW. Prevention of passively transferred experimental autoimmune myasthenia gravis by an in vitro selected RNA aptamer. FEBS Lett 2003;548:85-9
   PubMed Web of Science ®Google Scholar
• Kubik MF, Bell C, Fitzwater T, et al. Isolation and characterization of 2′-fluoro-, 2′-amino-, and 2′-fluoro-/amino-modified RNA ligands to human IFN-γ that inhibit receptor binding. J Immunol 1997;159:259-67
   PubMed Web of Science ®Google Scholar
• Kraus E, James W, Barclay AN. Cutting edge: Novel RNA ligands able to bind CD4 antigen and inhibit CD41 T lymphocyte function. J Immunol 1998;160:5209-12
   PubMed Web of Science ®Google Scholar
• Rhodes A, Deakin A, Spaull J, et al. The generation and characterization of antagonist RNA aptamers to human oncostatin M. J Biol Chem 2000;275:28555-61
   PubMed Web of Science ®Google Scholar
• Charlton J, Kirschenheuter GP, Smith D. Highly potent irreversible inhibitors of neutrophil elastase generated by selection from a randomized DNA-valine phosphonate library. Biochemistry 1997;36:3018-26
   PubMed Web of Science ®Google Scholar
• Lorger M, Engstler M, Homann M, Göringer HU. Targeting the variable surface of African trypanosomes with variant surface glycoprotein-specific, serum-stable RNA aptamers. Eukaryotic Cell 2003;2:84-94
   PubMed Web of Science ®Google Scholar
• Santulli-Marotto S, Nair SK, Rusconi C, et al. Multivalent RNA aptamers that inhibit CTLA-4 and enhance tumor immunity. Cancer Res 2003;63:7483-9
   PubMed Web of Science ®Google Scholar
• Hwang J, Fauzi H, Fukuda K, et al. Analysis of aptamer binding site for HCV-NS3 protease by alanine scanning mutagenesis. Nucleic Acids Symp Ser 2000;44:253-4
   PubMedGoogle Scholar
• Lato SM, Ozerova ND, He K, et al. Boron-containing aptamers to ATP. Nucleic Acid Res 2002;30:1401-7
   PubMed Web of Science ®Google Scholar
• Hirao I, Madin K, Endo Y, et al. RNA Aptamers that bind to and inhibit the ribosome-inactivating protein, Pepocin. J Biol Chem 2000;275:4943-8
   PubMed Web of Science ®Google Scholar